Antibody-like proteins that capture and neutralize SARS-CoV-2


To combat severe acute respiratory syndrome–related coronavirus 2 (SARS-CoV-2) and any unknown emerging pathogens in the future, the development of a rapid and effective method to generate high-affinity antibodies or antibody-like proteins is of critical importance. We here report high-speed in vitro selection of multiple high-affinity antibody-like proteins against various targets including the SARS-CoV-2 spike protein. The sequences of monobodies against the SARS-CoV-2 spike protein were successfully procured within only 4 days. Furthermore, the obtained monobody efficiently captured SARS-CoV-2 particles from the nasal swab samples of patients and exhibited a high neutralizing activity against SARS-CoV-2 infection (half-maximal inhibitory concentration, 0.5 nanomolar). High-speed in vitro selection of antibody-like proteins is a promising method for rapid development of a detection method for, and of a neutralizing protein against, a virus responsible for an ongoing, and possibly a future, pandemic.

Read full text: Antibody-like proteins that capture and neutralize SARS-CoV-2. T. KONDO, Y. IWATANI, K. MATSUOKA, T. FUJINO, S. UMEMOTO, Y. YOKOMAKU, K. ISHIZAKI, S. KITO, T. SEZAKI, G. HAYASHI, H. MURAKAMI, SCIENCE ADVANCES, 14 OCT 2020 : EABD3916

Keywords: antibody-like proteins, neutralization of SARS-CoV-2, monobodies.

The International Natural Product Sciences Taskforce (INPST) maintains up-to-date lists with conferencesgrants and funding opportunitiesjobs and open positions, and journal special issues with relevance for the area of phytochemistry and food chemistry, pharmacology, biotechnology, medicine and pharmacognosy research, and natural product science.

Join for free INPST as a member

INPST social media channels